Supporting pandemic response using genomics and bioinformatics: A case study on the emergent SARS-CoV-2 outbreak.


Journal

Transboundary and emerging diseases
ISSN: 1865-1682
Titre abrégé: Transbound Emerg Dis
Pays: Germany
ID NLM: 101319538

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 19 03 2020
revised: 30 03 2020
accepted: 07 04 2020
pubmed: 20 4 2020
medline: 15 7 2020
entrez: 20 4 2020
Statut: ppublish

Résumé

Pre-clinical responses to fast-moving infectious disease outbreaks heavily depend on choosing the best isolates for animal models that inform diagnostics, vaccines and treatments. Current approaches are driven by practical considerations (e.g. first available virus isolate) rather than a detailed analysis of the characteristics of the virus strain chosen, which can lead to animal models that are not representative of the circulating or emerging clusters. Here, we suggest a combination of epidemiological, experimental and bioinformatic considerations when choosing virus strains for animal model generation. We discuss the currently chosen SARS-CoV-2 strains for international coronavirus disease (COVID-19) models in the context of their phylogeny as well as in a novel alignment-free bioinformatic approach. Unlike phylogenetic trees, which focus on individual shared mutations, this new approach assesses genome-wide co-developing functionalities and hence offers a more fluid view of the 'cloud of variances' that RNA viruses are prone to accumulate. This joint approach concludes that while the current animal models cover the existing viral strains adequately, there is substantial evolutionary activity that is likely not considered by the current models. Based on insights from the non-discrete alignment-free approach and experimental observations, we suggest isolates for future animal models.

Identifiants

pubmed: 32306500
doi: 10.1111/tbed.13588
pmc: PMC7264654
doi:

Banques de données

GENBANK
['AY274119.3', 'AY291451.1', 'AY502923.1', 'AY502932.1', 'AY559083.1', 'AY559084.1', 'AY559087.1', 'KY417142.1', 'KY417152.1', 'KJ477102.1', 'KT006149.2', 'KT026453.1', 'KT029139.1', 'MG596802.1', 'MG596803.1']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1453-1462

Subventions

Organisme : Commonwealth Scientific and Industrial Research Organisation
Organisme : Coalition for Epidemic Preparedness Innovations

Informations de copyright

© 2020 The Authors. Transboundary and Emerging Diseases published by Blackwell Verlag GmbH.

Références

Euro Surveill. 2019 Jul;24(29):
pubmed: 31339094
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5108-13
pubmed: 16549795
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259
pubmed: 30931475
Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202
pubmed: 26953178
Nat Microbiol. 2020 Apr;5(4):529-530
pubmed: 32071422
J Virol. 2004 Jul;78(14):7846-51
pubmed: 15220462
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nature. 2001 Jul 19;412(6844):331-3
pubmed: 11460163
J Virol. 2010 Apr;84(7):3134-46
pubmed: 19906932
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nature. 2020 Mar;579(7798):183
pubmed: 32152596
Euro Surveill. 2020 Feb;25(5):
pubmed: 32019636
Transbound Emerg Dis. 2020 Jul;67(4):1453-1462
pubmed: 32306500
Rev Sci Tech. 2011 Apr;30(1):95-106
pubmed: 21809756
J Mol Biol. 2003 Aug 29;331(5):991-1004
pubmed: 12927536
BMC Evol Biol. 2004 Jun 28;4:21
pubmed: 15222897
Nat Commun. 2019 Feb 25;10(1):934
pubmed: 30804347
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2677-82
pubmed: 19188606
Bioinformatics. 2019 Nov 1;35(21):4453-4455
pubmed: 31070718
Natl Sci Rev. 2020 Jun;7(6):1012-1023
pubmed: 34676127
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793

Auteurs

Denis C Bauer (DC)

Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, Sydney, NSW, Australia.
Department of Biomedical Sciences, Macquarie University, NSW, Australia.

Aidan P Tay (AP)

Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, Sydney, NSW, Australia.

Laurence O W Wilson (LOW)

Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, Sydney, NSW, Australia.

Daniel Reti (D)

Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, Sydney, NSW, Australia.

Cameron Hosking (C)

Commonwealth Scientific and Industrial Research Organisation, Transformational Bioinformatics Group, Sydney, NSW, Australia.

Alexander J McAuley (AJ)

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Geelong, Vic, Australia.

Elizabeth Pharo (E)

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Geelong, Vic, Australia.

Shawn Todd (S)

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Geelong, Vic, Australia.

Vicky Stevens (V)

Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, Vic, Australia.

Matthew J Neave (MJ)

Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, Vic, Australia.

Mary Tachedjian (M)

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Geelong, Vic, Australia.

Trevor W Drew (TW)

Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Geelong, Vic, Australia.

Seshadri S Vasan (SS)

Commonwealth Scientific and Industrial Research Organisation, Health and Biosecurity, Geelong, Vic, Australia.
Department of Health Sciences, University of York, York, United Kingdom.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH